The Kim Lab is focused on understanding the genetic and epigenetic events involved in the initiation and progression of renal cell carcinoma (RCC) and bladder cancer. Through NextGeneration sequencing of primary human tumors and the use of genetically engineered mouse models (GEMMs), as well as in vitro systems, our goal is to identify the critical genomic and epigenetic changes that are drivers of RCC and bladder cancer. Our ultimate goal is to elucidate the functional consequences of these genomic events in order to pinpoint novel, high impact therapeutic targets for therapy.
Dr. Kim is the Chair, Committee for Genomic Research UNCseq: UNCseq video
Dr. Kim is the co-Director of UNC’s Mouse Phase 1 Unit (MP1U)